<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Discovery of antileishmanial hits in the 3-nitroimidazo[1,2-a]pyridine series via newly optimized tetrakis(dimethylamino)ethylene (TDAE) methodology at position 2</dc:title>
  <dc:creator>Jacquet, I.</dc:creator>
  <dc:creator>Paoli-Lombardo, R.</dc:creator>
  <dc:creator>Castera-Ducros, C.</dc:creator>
  <dc:creator>Pomares, H.</dc:creator>
  <dc:creator>/Bourgeade-Delmas, Sandra</dc:creator>
  <dc:creator>Vanelle, P.</dc:creator>
  <dc:creator>Primas, N.</dc:creator>
  <dc:subject>TDAE</dc:subject>
  <dc:subject>N-Tosylbenzylimine</dc:subject>
  <dc:subject>Leishmania</dc:subject>
  <dc:subject>Nitroaromatic compounds</dc:subject>
  <dc:subject>Nucleophilic aromatic substitution</dc:subject>
  <dc:subject>Palladium-catalyzed cross-coupling</dc:subject>
  <dc:subject>3-Nitroimidazo[1,2-a]pyridine</dc:subject>
  <dc:description>To explore the antileishmanial structure-activity relationships at position 2 of the 3-nitroimida-zo[1,2-a]pyridine scaffold, we developed a new synthetic method using Tetrakis(dimethylamino)ethylene (TDAE) and N-tosylbenzylimines. This original synthetic route was optimized to provide simple and reproducible access to diverse analogues functionalized at position 2. A library of 25 new derivatives was generated via efficient diversification at position 8 using nucleophilic aromatic substitution (SNAr) and Suzuki-Miyaura cross-coupling reactions. The 8-brominated analogues emerged as the most promising series, with six compounds exhibiting submicromolar activity against Leishmania infantum axenic amastigotes. Further substitution at position 8 with 4-pyridinyl or para-chlorothiophenol groups significantly decreased potency. The most active compound was also active on intramacrophagic amastigotes (half maximal inhibitory concentration (IC50) = 0.35 mu M) without displaying any cytotoxicity on THP1 cell line (50 % cytotoxic concentration (CC50) &gt; 100 mu M). The reduction of its nitro group afforded an amino analogue, which retained antileishmanial activity (IC50 = 2.77 mu M), indicating potential alternative mechanisms of action beyond nitro bioactivation. Despite its low solubility (&lt;1 mu M), this scaffold represents a novel and versatile entry point for antileishmanial drug discovery.</dc:description>
  <dc:date>2026</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010096002</dc:identifier>
  <dc:identifier>fdi:010096002</dc:identifier>
  <dc:identifier>Jacquet I., Paoli-Lombardo R., Castera-Ducros C., Pomares H., Bourgeade-Delmas Sandra, Vanelle P., Primas N.. Discovery of antileishmanial hits in the 3-nitroimidazo[1,2-a]pyridine series via newly optimized tetrakis(dimethylamino)ethylene (TDAE) methodology at position 2. 2026, 304, 118506 [14 ]</dc:identifier>
  <dc:language>EN</dc:language>
</oai_dc:dc>
